Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
Status:
Terminated
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This is a clinical research study designed to evaluate whether the administration of a
vaccine to patients after transplant consisting of a minor histocompatibility antigen (mHag
peptide) mixed with G-CSF (a drug intended to stimulate the immune system) can stimulate
increased graft versus leukemia (GVL) responses without causing graft-versus-host disease
(GVHD).